Prostate cancer is the most common malignancy among men in the United States, with its advanced form—metastatic castration-resistant prostate cancer (mCRPC)—posing a significant healthcare burden. Alarmingly, the incidence of mCRPC is rising at a rate of 5% annually, necessitating urgent developments in drug discovery and treatment. The disparity in its prevalence is also a cause...